A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma

Trial Profile

A Phase IIa Study of Sotatercept on Bone Mass and Turnover in Patients With Multiple Myeloma

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs Sotatercept (Primary)
  • Indications Bone disorders; Multiple myeloma
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 30 Aug 2016 Status changed from recruiting to withdrawn prior to enrolment.
    • 22 Feb 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Jan 2017 as reported by ClinicalTrials.gov record.
    • 02 Oct 2015 Planned primary completion date changed from 1 Oct 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top